Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.

Katherine I FosterKenna R M ShawJeff JinShannon N WestinTimothy A YapDeanna M GlassmanAmir A JazaeriJose Alejandro Rauh-HainSanghoon LeeBryan M FellmanZhenlin JuYuexin Liu Nicole D Fleming Anil K Sood

Published in: Cancer (2023)

Although more and more patients with ovarian cancer are undergoing tumor-based next-generation sequencing to identify genetic mutations in their tumors, the benefits of such testing are not well established. In a group of over 400 patients with ovarian cancer who underwent tumor-based next-generation sequencing in the course of their treatment, nearly all patients had one or more genetic alterations detected, and one out of four patients had a mutation that qualified them for a personalized treatment option.

Keyphrases

end stage renal disease
copy number
high grade
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
genome wide
gene expression
patient reported